Comparing TIPS Procedure Versus Standard Medication for Treating Hepatorenal Syndrome-Acute Kidney Injury in Cirrhosis Patients
Led by Jena University Hospital · Updated on 2024-11-18
124
Participants Needed
14
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
This research aims to compare the effectiveness and safety of a procedure called TIPS transjugular intrahepatic portosystemic shunt versus standard drug therapy in patients with cirrhosis who develop hepatorenal syndrome-acute kidney injury HRS-AKI at various stages. Cirrhosis can lead to serious complications including kidney injury, and while current treatments improve kidney function, risks remain high. The study evaluates whether reducing pressure in the portal vein through TIPS placement can improve outcomes compared to standard care with drugs like terlipressin and albumin.
Participants will be randomly assigned to receive either TIPS implantation plus standard care or standard medication therapy alone, which mainly involves terlipressin and albumin noradrenaline may be used if terlipressin is not tolerated. The TIPS procedure creates a pathway to reduce portal vein pressure, potentially improving kidney function. The study is multicenter and will follow patients for at least 12 months to compare survival without liver transplant and other health outcomes.
Throughout the study, participants will be monitored with regular assessments including survival rates up to 12 months, kidney function improvement, need for additional treatments, hospital stays, and quality of life measures. Safety and complications will also be tracked. The study aims to provide detailed information on how TIPS compares to standard drug therapy over time in patients with cirrhosis and HRS-AKI, with a focus on transplant-free survival and kidney health.
CONDITIONS
Brief Title
HRS-AKI Treatment With TIPS in Patients With Cirrhosis
Research Team
C
Cristina Ripoll, Prof. Dr.
A
Alexander Zipprich, Prof. Dr.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Patients diagnosed with cirrhosis confirmed by histology, liver stiffness, or clear signs in ultrasound, endoscopy, or blood tests
Clinically evident ascites caused by portal hypertension
Diagnosis of hepatorenal syndrome-acute kidney injury (HRS-AKI)
Age between 18 and 80 years at consent
ECOG performance status less than 4 before hospital admission
Willingness to comply with study follow-up and signed informed consent
Female participants of childbearing potential must have a negative pregnancy test within 7 days before procedure and agree to use effective birth control during the study; exemptions apply for sterile, infertile, or postmenopausal women
You will not qualify if you...
Use of nephrotoxic drugs (NSAIDs, aminoglycosides, or high-dose iodinated contrast) within 72 hours before AKI diagnosis
Improvement of kidney function after 1 day of stopping diuretics and albumin plasma volume expansion
Uncontrolled shock within 48 hours before randomization
Uncontrolled infection despite 48 hours of antibiotics
Cirrhosis due to primary heart disease (cardiac cirrhosis)
Contraindications to TIPS such as high bilirubin, recurrent hepatic encephalopathy, pulmonary hypertension, or aortic stenosis
Presence of portal, splenic, or mesenteric vein thrombosis
Significant cardiac disease (NYHA class II or higher), diastolic dysfunction grade 3, or reduced systolic function (ejection fraction ≤ 50%)
Acute-on-chronic liver failure grade 3
Creatinine levels above 442 µmol/L
Acute variceal bleeding needing pre-emptive TIPS or terlipressin
Refractory ascites as defined by specific treatment responses
Hepatocellular carcinoma outside Milan criteria or tumors in puncture tract
Benign liver tumors (except regenerative nodules) in puncture tract
Existing TIPS placement or prior liver transplantation
Comorbidities causing life expectancy under 1 year
Concurrent enrollment in other investigational trials
Pregnancy or breastfeeding
Suspected noncompliance with study participation
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person) for screening and enrollment
Treatment
Duration - Up to 12 months
Participants receive either standard medication therapy with terlipressin and albumin or a transjugular intrahepatic portosystemic shunt (TIPS) implant along with standard therapy to treat hepatorenal syndrome-acute kidney injury (HRS-AKI).
Regular treatment and follow-up visits during the treatment period
Follow-up
Duration - Up to 12 months after baseline
Participants are monitored for outcomes including survival, recurrence of HRS-AKI, liver transplant status, and quality of life measures after treatment.
Approximately monthly visits during follow-up for up to 12 months
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Randomized Trial of Dapagliflozin Plus Standard Care Versus Standard Care Alone
in Adults with Cirrhosis and Ascites to Improve Clinical Outcomes
Using 3D Magnetic Resonance Elastography to Assess Cirrhosis, Advanced Chronic Liver Disease, and Portal Hypertension
A Prospective Multicenter Study to Develop a Non-Invasive Risk Stratification Method
A Phase 2 Double-Blind Study Comparing Kidney Protection of Cilastatin Versus Thiosulfate
in Women Undergoing Debulking Surgery with Heated Intraperitoneal Cisplatin Chemotherapy
Study to Validate and Develop the Multifactorial Dynamic Perfusion Index MDPI for Predicting Kidney Injury and Other Complications After Cardiac Surgery with Cardiopulmonary Bypass in Adults and Infants
COPE-AKI Trial Evaluating a Team-Based Care Approach for Patients After Acute Kidney Injury to Improve Hospital-Free Days and Kidney Outcomes
Comparing Kidney Injury Risks of Vancomycin with Piperacillin-Tazobactam Versus Vancomycin with Cefepime in Hospitalized Adults
Study of Early Restart Versus Usual Care of Renin-Angiotensin System Inhibitors After Acute Kidney Injury in Hospitalized Adults
Retrospective Study of Treatment Outcomes for Hepatorenal Syndrome Patients at Methodist Dallas Medical Center
Improving Care for Children Ages 1 to 18 with Acute Kidney Injury Using a Mobile Health Educational Tool
Safety Study of Siplizumab as Induction Therapy in Adults With Autoimmune Liver Diseases Undergoing Liver Transplant